Jean Marie Franzini
The evolution of tumor genomic profiling in personalized medicine requires a strategic management of genetic testing. Among the available technologies, Next Generation Sequencing (NGS), allows simultaneous testing for a wide range of genes. However NGS test benefits still need to be assessed and compared to the single-gene test (SGT) approach to provide recommendations for a strategic adoption in the Italian NHS setting.
The study aims to assess the differential impact of NGS and single-gene tests on the diagnostic-therapeutic process of patients with advanced non-small-cell lung cancer (aNSCLC) in a selection of Italian hospitals. On this purpose, we designed a decision model structured in two arms, SGT and NGS approaches, and three stages i.e. diagnostic biopsy, genetic testing and therapy initiation.